Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Patent: 8,277,807

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,277,807
Title:Pharmaceutical combinations
Abstract: The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): ##STR00001## or salts, tautomers, solvates and N-oxides thereof; wherein R.sup.1 is hydroxy or hydrogen; R.sup.2 is hydroxy; methoxy or hydrogen; provided that at least one of R.sup.1 and R.sup.2 is hydroxy; R.sup.3 is selected from hydrogen; halogen; cyano; optionally substituted C.sub.1-5 hydrocarbyl and optionally substituted C.sub.1-5 hydrocarbyloxy; R.sup.4 is selected from hydrogen; a group --(O).sub.n--R.sup.7 where n is 0 or 1 and R.sup.7 is an optionally substituted acyclic C.sub.1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C.sub.1-5 hydrocarbyl-amino; or R.sup.3 and R.sup.4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR.sup.5R.sup.6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 inhibitors.
Inventor(s): Gallagher; Neil James (Basel, CH), Lyons; John Francis (Cambridge, GB), Thompson; Neil Thomas (Cambridge, GB), Yule; Stephen Murray (Cambridge, GB), Murray; Christopher William (Cambridge, GB)
Assignee: Astex Therapeutics Limited (Cambridge, GB)
Application Number:12/445,141
Patent Claims:see list of patent claims

Details for Patent 8,277,807

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Try it Free 2026-10-12
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Try it Free 2026-10-12
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2026-10-12
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Try it Free 2026-10-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.